From cirrhosis to hepatocellular carcinoma in HCV-infected patients: Genes involved in tumor progression

European Review for Medical and Pharmacological Sciences

Volumn 16, Issue 8, 2012, Pages 995-1000

  Wang, Y ^a   Li, J ^a   Chen, J ^a   Liu, L ^a   Peng, Z ^a   Ding, J ^a   Ding, K ^a  

^a Fengxian Center Hospital   (China)

Author keywords

Cirrhosis; Differentially co express genes; Hepatocellular Carcinoma

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; MYC PROTEIN; TRANSCRIPTION FACTOR DELTA FOSB; TRANSCRIPTION FACTOR FKHR; FORKHEAD TRANSCRIPTION FACTOR; FOSB PROTEIN, HUMAN; FOXO1 PROTEIN, HUMAN; PROTEIN C FOS;

ARTICLE; BIOINFORMATICS; CANCER DIAGNOSIS; CANCER RISK; EARLY DIAGNOSIS; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC RISK; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MICROARRAY ANALYSIS; MOLECULAR PATHOLOGY; PROTEIN EXPRESSION; RIBOSOME; SPLICEOSOME; STEROIDOGENESIS; TUMOR GROWTH; DISEASE COURSE; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HEPATITIS C; HUMAN; LIVER TUMOR; PHYSIOLOGY;

CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTO-ONCOGENE PROTEINS C-FOS;

EID: 84865828614     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. EL-SERAG HB, RUDOLPH KL. Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576.
2. AVILA MA, BERASAIN C, SANGRO B, PRIETO J. New therapies for hepatocellular carcinoma. Oncogene 2006; 25: 3866-3884.
3. BOSCH FX, RIBES J, BORRAS J. Epidemiology of primary liver cancer. Semin Liver Dis 1999; 19: 271-285.
4. TANAKA Y, HANADA K, MIZOKAMI M, YEO AE, SHIH JW, GOJOBORI T, ALTER HJ. A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci U S A 2002; 99: 15584-15589.
5. BRUIX J, LLOVET JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002; 35: 519-524.
6. HOOFNAGLE JH. Course and outcome of hepatitis C. Hepatology 2002; 36: S21-29.
7. TONG MJ, EL-FARRA NS, REIKES AR, CO RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463-1466.
8. ARAVALLI RN, STEER CJ, CRESSMAN EN. Molecular mechanisms of hepatocellular carcinoma. Hepatology 2008; 48: 2047-2063.
9. HERBST A, KOLLIGS FT. Wnt signaling as a therapeutic target for cancer.Methods Mol Biol 2007; 361: 63-91.
10. MERLE P, KIM M, HERRMANN M, GUPTE A, LEFRANCOIS L, CALIFANO S, TREPO C, TANAKA S, VITVITSKI L, DE LA MONTE S, WANDS Jr. Oncogenic role of the frizzled-7/beta-catenin pathway in hepatocellular carcinoma. J Hepatol 2005; 43: 854-862.
11. HICKMAN ES, MORONI MC, HELIN K. The role of p53 and pRB in apoptosis and cancer. Curr Opin Genet Dev 2002; 12: 60-66.
12. HOOPER ML. The role of the p53 and Rb-1 genes in cancer, development and apoptosis. J Cell Sci Suppl 1994; 18: 13-17.
13. DYNLACHT BD, FLORES O, LEES JA, HARLOW E. Differential regulation of E2F transactivation by cyclin/cdk2 complexes.Genes Dev 1994; 8: 1772-1786.
14. ZHAO LJ, WANG L, REN H, CAO J, LI L, KE JS, QI ZT. Hepatitis C virus E2 protein promotes human hepatoma cell proliferation through the MAPK/ERK signaling pathway via cellular receptors. Exp Cell Res 2005; 305: 23-32.
15. YOSHIKAWA H, MATSUBARA K, QIAN GS, JACKSON P, GROOPMAN JD, MANNING JE, HARRIS CC, HERMAN JG. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet 2001; 28: 29-35.
16. MAS VR, MALUF DG, ARCHER KJ, YANEK K, BORNSTEIN K, FISHER RA. Proteomic analysis of HCV cirrhosis and HCV-induced HCC: Identifying biomarkers for monitoring HCV-cirrhotic patients awaiting liver transplantation. Transplantation 2009; 87: 143-152.
17. GEBO KA, CHANDER G, JENCKES MW, GHANEM KG, HERLONG HF, TORBENSON MS, EL-KAMARY SS, Bass EB. Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: A systematic review. Hepatology 2002; 36: S84-92.
18. SHERMAN M. Alphafetoprotein: An obituary. J Hepatol 2001; 34: 603-605.
19. DANIELE B, BENCIVENGA A, MEGNA AS, TINESSA V. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology 2004; 127: S108-112.
20. RAPACCINI GL, POMPILI M, CATURELLI E, COVINO M, LIPPI ME, BECCARIA S, CEDRONE A, RICCARDI L, SIENA DA, GASBARRINI G. Hepatocellular carcinomas <2 cm in diameter complicating cirrhosis: Ultrasound and clinical features in 153 consecutive patients. Liver Int 2004; 24: 124-130.
21. LEE MJ, YU GR, PARK SH, CHO BH, AHN JS, PARK HJ, SONG EY, KIM DG. Identification of cystatin B as a potential serum marker in hepatocellular carcinoma. Clin Cancer Res 2008; 14: 1080-1089.
22. ZINKIN NT, GRALL F, BHASKAR K, OTU HH, SPENTZOS D, KALMOWITZ B, WELLS M, GUERRERO M, ASARA JM, LIBERMANN TA, AFDHAL NH. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clin Cancer Res 2008;14: 470-477.
23. KANEHISA M. The KEGG database. Novartis Foundation symposium 2002; 247: 91-101; discussion 01-3, 19-28, 244-252.
24. KANEHISA M, GOTO S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res 2000; 28: 27-30.
25. CARTER SL, BRECHBUHLER CM, GRIFFIN M, BOND AT. Gene co-expression network topology provides a framework for molecular characterization of cellular state. Bioinformatics 2004; 20: 2242-2250.
26. CHOI JK, YU U, YOO OJ, KIM S. Differential coexpression analysis using microarray data and its application to human cancer. Bioinformatics 2005; 21: 4348-4355.
27. DE LA FUENTE A. From 'differential expression' to 'differential networking'-identification of dysfunctional regulatory networks in diseases. Trends Genet 2010; 26: 326-333.
28. TEAM RDC. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing 2011.
29. SHANNON P, MARKIEL A, OZIER O, BALIGA NS, WANG JT, RAMAGE D, AMIN N, SCHWIKOWSKI B, IDEKER T. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res 2003; 13: 2498-2504.
30. FRANCESCONI M, REMONDINI D, NERETTI N, SEDIVY JM, COOPER LN, VERONDINI E, MILANESI L, CASTELLANI G. Reconstructing networks of pathways via significance analysis of their intersections. BMC Bioinformatics 2008;9 Suppl 4: S9.
31. ZHENG F, LIAO YJ, CAI MY, LIU YH, LIU TH, CHEN SP, BIAN XW, GUAN XY, LIN MC, ZENG YX, KUNG HF, XIE D. The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. Gut 2012; 61: 278-289.
32. LOTFY M, EL-KENAWY AEL M, ABDEL-AZIZ MM, ELKADY I, TALAAT A. Elevated renin levels in patients with liver cirrhosis and hepatocellular carcinoma. Asian Pac J Cancer Prev 2010; 11: 1263-1266.
33. SOBER S, LAAN M, ANNILO T. MicroRNAs miR-124 and miR-135a are potential regulators of the mineralocorticoid receptor gene (NR3C2) expression. Biochem Biophys Res Commun 2010; 391: 727-732.
34. THURMOND TS, STAPLES JE, SILVERSTONE AE, GASIEWICZ TA. The aryl hydrocarbon receptor has a role in the in vivo maturation of murine bone marrow B lymphocytes and their response to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol Appl Pharmacol 2000; 165: 227-236.
35. NEBERT DW, ROE AL, DIETER MZ, SOLIS WA, YANG Y, DALTON TP. Role of the aromatic hydrocarbon receptor and [Ah] gene battery in the oxidative stress response, cell cycle control, and apoptosis. Biochem Pharmacol 2000; 59: 65-85.
36. MARLOWE JL, PUGA A. Aryl hydrocarbon receptor, cell cycle regulation, toxicity, and tumorigenesis. J Cell Biochem 2005; 96: 1174-1184.
37. KOHN KW. Molecular interaction map of the mammalian cell cycle control and DNA repair systems. Mol Biol Cell 1999; 10: 2703-2734.
38. YUEN MF, WU PC, LAI VC, LAU JY, LAI CL. Expression of c-Myc, c-Fos, and c-jun in hepatocellular carcinoma. Cancer 2001; 91: 106-112.
39. SOUCEK L, WHITFIELD J, MARTINS CP, FINCH AJ, MURPHY DJ, SODIR NM, KARNEZIS AN, SWIGART LB, NASI S, EVAN GI. Modelling Myc inhibition as a cancer therapy. Nature 2008; 455: 679-683.
40. FERDOUS A, MORRIS J, ABEDIN MJ, COLLINS S, RICHARDSON JA, HILL JA. Forkhead factor FoxO1 is essential for placental morphogenesis in the developing embryo. Proc Natl Acad Sci U S A 2011; 108: 16307-1612.
41. MYATT SS, LAM EW. The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer 2007; 7: 847-859.
42. JOCHUM W, PASSEGUE E, WAGNER EF. AP-1 in mouse development and tumorigenesis. Oncogene 2001; 20: 2401-2412.
43. SHAULIAN E, KARIN M. AP-1 in cell proliferation and survival. Oncogene 2001; 20: 2390-2400.
44. MAS VR, MALUF DG, STRAVITZ R, DUMUR CI, CLARK B, RODGERS C, FERREIRA-GONZALEZ A, FISHER RA. Hepatocellular carcinoma in HCV-infected patients awaiting liver transplantation: Genes involved in tumor progression. Liver Transpl 2004; 10: 607-620.